2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 1/2
1
Status
Completed
3
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
2
Head & Neck
1
Gynecologic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Recurrent Platinum Resistant Ovarian Cancer
1
Rectal Neoplasms
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Carcinoma
1
Adenoviridae Infections
1
Interventions
Cyclophosphamide
626
pembrolizumab
505
Paclitaxel
456
Gemcitabine
439
Carboplatin
437
Cisplatin
420
Radiotherapy
382
fludarabine
367
Nivolumab
340
Docetaxel
278
Bevacizumab
276
Irinotecan
258
Magnetic Resonance Spectroscopy
245
Fluorouracil
229
Dexamethasone
225
Specimen Handling
223
Capecitabine
218
Rituximab
206
Oxaliplatin
201
Cytarabine
201
Ipilimumab
198
Temozolomide
197
Biopsy
197
fludarabine phosphate
194
Etoposide
181
Lenalidomide
176
Doxorubicin
175
Leucovorin
174
Cetuximab
171
Injections
170
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1
×
enadenotucirev
×
Clear all
NCT03916510
2025-02-06
CEDAR
University of Oxford
Phase 1
Completed
12 enrolled
13 charts
NCT02636036
2021-11-09
SPICE
Akamis Bio
Phase 1
Completed
51 enrolled
NCT02028117
2021-05-13
OCTAVE
Akamis Bio
Phase 1
Completed
38 enrolled